Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistBased on limited metadata, this FDA Warning Letter issued June 3, 2020, addresses Auro Pharmacies, Inc., operating as Central Drugs Compounding Pharmacy, a drug compounding facility. While the specific violations are not detailed in the available metadata, the warning relates to pharmaceutical drug products and compounding pharmacy operations. The letter falls under FDA's drug product regulatory authority, though the specific issuing office is not identified. Without access to the full letter text, the precise nature and scope of the compliance issues cannot be determined from this metadata alone.